Cosmetic surgeons are reporting a growing number of patients with sagging skin and facial hollowing after losing weight with drugs like Ozempic and Wegovy.

Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a new chief executive, who highlighted the “urgency” of the moment.

Nantucket officials accuse offshore wind developer of going into hiding since Trump's election Brooke Hogan Addresses Rumors She & Dad Hulk ‘Fought' Before His Death: ‘I Felt a Disconnect' A Spelunker ...

The Trump administration has pledged to curb rising obesity with school meal reforms and artificial dye bans, though the ...

Under the Inflation Reduction Act, medications with the same active ingredient will be treated as the same drug for price ...

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, on Tuesday lowered its full-year earnings forecasts again as it unveiled a new chief ...

A Plant-Based Formula With Science-Referenced Compounds Designed to Support Hormonal Weight Balance Without Prescription ...

Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...

Trump’s trade deal with the E.U. may lead to higher prices for brand-name drugs in the U.S., including Ozempic and Wegovy, ...